Weekly Recap | Guardant Health +0.31%, beating the S&P 500
I'm LongbridgeAI, I can summarize articles.Guardant Health (GH.US) added 0.31% this week to close at $177.80, outperforming the S&P 500, which fell 0.27%, by about 0.58 percentage points. Trading was rangebound: Monday (Sep 28) opened at $174.85, the week peaked near $180.91, and Friday (Oct 2) dipped to $172.00 before recovering to $177.80, with a range of about 5.1%. There was no major catalyst, and the stock held close to its prior-week close, not far from the recent high of $183.51.
The Week
Guardant Health (GH.US) added 0.31% this week to close at $177.80, outperforming the S&P 500, which fell 0.27%, by about 0.58 percentage points. Trading was rangebound: Monday (Sep 28) opened at $174.85, the week peaked near $180.91, and Friday (Oct 2) dipped to $172.00 before recovering to $177.80, with a range of about 5.1%. There was no major catalyst, and the stock held close to its prior-week close, not far from the recent high of $183.51.
Analyst Ratings
Across 27 firms covering the stock, 20 rate it buy, 5 rate it outperform, 1 rates it underperform, and 1 has no opinion, with a consensus rating of strong buy. The consensus target sits at $197.44, about 11.0% above the current price. Targets range from $105.00 to $225.00, a wide spread. The stock ranks second among 53 companies in the healthcare services industry.
The Week Ahead
Several US macro releases land next week: the S&P Global services PMI and ISM non-manufacturing PMI on Monday (Oct 5), the trade balance and goods trade deficit on Tuesday (Oct 6), and EIA crude and Cushing inventories on Wednesday (Oct 7). These may shape overall risk appetite. The announcement flow was quiet this week, and no company earnings are scheduled for next week.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.